NCT00179660View on ClinicalTrials.gov

Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Non-Hodgkins Lymphoma
Interventions
DRUG

Lenalidomide

Capsules for oral administration.

Trial Locations (8)

10466

New York Medical Center, MBCCOP, The Bronx

33136

Sylvester Cancer CenterUniversity Of Miami, Miami

54601

Gunderson Clinic, Ltd, La Crosse

55905

Mayo Clinic, Rochester

85259

Mayo Clinic Scottsdale, Scottsdale

92708

Pacific Coast Hematology/Oncology Medical Group, Onc., Fountain Valley

95817

UC David Cancer Center, Sacramento

68198-6805

University of Nebraska, Omaha

Sponsors
All Listed Sponsors
collaborator

Prologue Research International

INDUSTRY

lead

Celgene Corporation

INDUSTRY

NCT00179660 - Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) | Biotech Hunter | Biotech Hunter